Valuation: Everest Organics Limited

Market Cap 1.98B 20.78M 18.24M 16.79M 15.65M 29.51M 30.11M 202M 78.26M 970M 78.02M 76.34M 3.37B P/E 2024
675x
P/E 2025 -190x
Enterprise Value 2.39B 25.12M 22.05M 20.3M 18.92M 35.67M 36.4M 244M 94.59M 1.17B 94.31M 92.27M 4.08B EV / Sales 2024
0.75x
EV / Sales 2025 1.79x
Free-Float
23.02%
Yield 2024 *
-
Yield 2025 -
1 day+0.14%
1 week-9.04%
Current month+0.14%
1 month-6.82%
3 months+22.88%
6 months-50.57%
Current year-50.57%
1 week 245
Extreme 245
274
1 month 217
Extreme 217
278.8
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 101
Extreme 101
536.4
5 years 95
Extreme 95
536.4
10 years 28.65
Extreme 28.65
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 28/09/2015
Director TitleAgeSince
Director/Board Member 71 13/11/2024
Director/Board Member 47 29/09/2007
Director/Board Member 48 30/07/2014
Change 5-day change 1-year change 3-year change Capi.($)
+0.14%-9.04%-31.04%+145.17% 25.64M
+0.20%-0.10%+11.37%+77.46% 47.26B
-1.30%-0.42%+49.14%+102.33% 35B
-0.59%+1.65%-3.27%+43.52% 12.52B
-0.31%-0.27%+12.05%+90.24% 11.74B
+2.59%-2.72%+29.46%+115.95% 8.67B
+0.58%+1.00%+21.32%+44.72% 7.05B
-0.84%+1.67%+51.89%-9.13% 6.9B
-1.92%-0.80%+23.27%+219.81% 6.58B
+7.24%+10.32%-27.74%+9.65% 5.23B
Average +0.58%+0.48%+13.64%+83.97% 14.1B
Weighted average by Cap. -0.01%+0.72%+22.19%+82.31%

Financials

2024 2025
Net sales 1.98B 20.83M 18.29M 16.83M 15.69M 29.58M 30.18M 202M 78.44M 972M 78.21M 76.51M 3.38B 1.6B 16.82M 14.77M 13.6M 12.67M 23.89M 24.38M 164M 63.36M 785M 63.17M 61.8M 2.73B
Net income 1.39M 14.64K 12.86K 11.83K 11.03K 20.79K 21.22K 142K 55.14K 683K 54.97K 53.79K 2.38M -12.9M -136K -119K -110K -102K -193K -197K -1.32M -511K -6.33M -510K -499K -22.04M
Net Debt 570M 5.99M 5.26M 4.84M 4.51M 8.51M 8.68M 58.24M 22.56M 280M 22.5M 22.01M 973M 412M 4.34M 3.81M 3.51M 3.27M 6.16M 6.29M 42.16M 16.33M 202M 16.29M 15.93M 704M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
355
Date Price Change Volume
01/07/26 250.00 +0.14% 1,124
30/06/26 ₹249.65 -1.62% 2,659
29/06/26 ₹253.75 -4.64% 628
25/06/26 ₹266.10 -2.60% 670
24/06/26 ₹273.20 -0.60% 377
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock